Current and emerging therapies for managing hyperphagia and obesity in Prader‐Willi syndrome: A narrative review

Ghrelin octanoylation by ghrelin O-acyltransferase: Unique protein biochemistry underlying metabolic signaling

(2019) James L. Hougland   BIOCHEMICAL SOCIETY TRANSACTIONS

Hormonal and metabolic effects of carbohydrate restriction in children with Prader Willi syndrome

(2019) Krystal A. Irizarry et al.   CLINICAL ENDOCRINOLOGY

Changes in Health-Related Outcomes in Youth With Obesity in Response to a Home-Based Parent-Led Physical Activity Program

(2019) Daniela A. Rubin et al.   JOURNAL OF ADOLESCENT HEALTH

Physical exercise and Prader‐Willi syndrome: A systematic review

(2019) Javier S. Morales et al.   CLINICAL ENDOCRINOLOGY

Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications

(2019) Arulkumar Nagappan et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes

(2019) Huey-Jing Huang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial

(2019) Bernard Zinman et al.   DIABETES CARE

A randomized pilot efficacy and safety trial of diazoxide choline controlled-release in patients with Prader-Willi syndrome

(2019) Virginia Kimonis et al.   PLoS One

Functional group and stereochemical requirements for substrate binding by ghrelin O -acyltransferase revealed by unnatural amino acid incorporation

(2018) Elizabeth R. Cleverdon et al.   BIOORGANIC CHEMISTRY

Hypothalamic loss of Snord116 recapitulates the hyperphagia of Prader-Willi syndrome

(2018) Joseph Polex-Wolf et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular genetic classification in Prader-Willi syndrome: a multisite cohort study

(2018) Merlin G Butler et al.   JOURNAL OF MEDICAL GENETICS

Preclinical Efficacy and Safety of the Novel Antidiabetic, Antiobesity MetAP2 Inhibitor ZGN-1061

(2018) Bryan F. Burkey et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Chronic diazoxide treatment decreases fat mass and improves endurance capacity in an obese mouse model of Prader-Willi syndrome

(2018) Jocelyn M. Bischof et al.   MOLECULAR GENETICS AND METABOLISM

The Oxytocin Receptor: From Intracellular Signaling to Behavior

(2018) Benjamin Jurek et al.   PHYSIOLOGICAL REVIEWS

High levels of caregiver burden in Prader-Willi syndrome

(2018) Nathalie Kayadjanian et al.   PLoS One

AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial

(2018) Soraya Allas et al.   PLoS One

Insights into the Allosteric Mechanism of Setmelanotide (RM-493) as a Potent and First-in-Class Melanocortin-4 Receptor (MC4R) Agonist To Treat Rare Genetic Disorders of Obesity through an in Silico Approach

(2018) Bethany A. Falls et al.   ACS Chemical Neuroscience

Dietary intake in youth with prader-willi syndrome

(2018) Michelle L. Mackenzie et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases

(2018) Christoffer Clemmensen et al.   Nature Reviews Endocrinology

Obesity management in Prader–Willi syndrome: current perspectives

(2018) Antonino Crinò et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

The Use of Oxytocin to Improve Feeding and Social Skills in Infants With Prader–Willi Syndrome

(2017) Maïthé Tauber et al.   PEDIATRICS

Cannabidiol: State of the art and new challenges for therapeutic applications

(2017) Simona Pisanti et al.   PHARMACOLOGY & THERAPEUTICS

Evaluation of a melanocortin-4 receptor (MC4R) agonist (Setmelanotide) in MC4R deficiency

(2017) Tinh-Hai Collet et al.   Molecular Metabolism

A review of chemosensory perceptions, food preferences and food-related behaviours in subjects with Prader–Willi Syndrome

(2016) Lorelei Martínez Michel et al.   APPETITE

Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist

(2016) Jocelyn M Bischof et al.   BRITISH JOURNAL OF PHARMACOLOGY

Promising effects of oxytocin on social and food-related behaviour in young children with Prader-Willi syndrome: a randomized, double-blind, controlled crossover trial

(2016) R.J. Kuppens et al.   CLINICAL ENDOCRINOLOGY

Safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-531, a first-in-class analogue of unacylated ghrelin, in healthy and overweight/obese subjects and subjects with type 2 diabetes

(2016) S. Allas et al.   DIABETES OBESITY & METABOLISM

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials

(2016) Karolin Bettge et al.   DIABETES OBESITY & METABOLISM

Prader-Willi syndrome and atypical submicroscopic 15q11-q13 deletions with or without imprinting defects

(2016) Maaz Hassan et al.   European Journal of Medical Genetics

Prevalence and phenotypic characterization of MC4R variants in a large pediatric cohort

(2016) H Vollbach et al.   INTERNATIONAL JOURNAL OF OBESITY

The octanoylated energy regulating hormone ghrelin: An expanded view of ghrelin’s biological interactions and avenues for controlling ghrelin signaling

(2016) Elizabeth R. Cleverdon et al.   MOLECULAR MEMBRANE BIOLOGY

Melanocortin-4 receptor–regulated energy homeostasis

(2016) Michael J Krashes et al.   NATURE NEUROSCIENCE

Laparoscopic sleeve gastrectomy in children and adolescents with Prader-Willi syndrome: a matched-control study

(2016) Aayed R. Alqahtani et al.   Surgery for Obesity and Related Diseases

Growth hormone therapy for Prader–Willi syndrome: challenges and solutions

(2016) Graziano Grugni et al.   Therapeutics and Clinical Risk Management

Targeting the endocannabinoid/CB1 receptor system for treating obesity in Prader–Willi syndrome

(2016) Ibrahim Knani et al.   Molecular Metabolism

Metabolic profiling in Prader-Willi syndrome and nonsyndromic obesity: sex differences and the role of growth hormone

(2015) Krystal A. Irizarry et al.   CLINICAL ENDOCRINOLOGY

Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists

(2015) Sten Madsbad   DIABETES OBESITY & METABOLISM

Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial

(2015) D. D. Kim et al.   DIABETES OBESITY & METABOLISM

Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice

(2015) C. Clemmensen et al.   EMBO Molecular Medicine

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Weight Loss in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

(2015) Feng Sun et al.   Journal of Diabetes Research

Dietary Modulation of Gut Microbiota Contributes to Alleviation of Both Genetic and Simple Obesity in Children

(2015) Chenhong Zhang et al.   EBioMedicine

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

(2015) Jessica E. Potts et al.   PLoS One

Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome

(2014) Yuji Oto et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

A double-blind randomized controlled trial of oxytocin nasal spray in Prader Willi syndrome

(2014) Stewart L. Einfeld et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Highly restricted deletion of the SNORD116 region is implicated in Prader–Willi Syndrome

(2014) Eric Bieth et al.   EUROPEAN JOURNAL OF HUMAN GENETICS

Liraglutide as a Potentially Useful Agent for Regulating Appetite in Diabetic Patients with Hypothalamic Hyperphagia and Obesity

(2014) Takao Ando et al.   INTERNAL MEDICINE

Hyperphagia: Current concepts and future directions proceedings of the 2nd international conference on hyperphagia

(2014) Steven B. Heymsfield et al.   Obesity

GLP-1 receptor agonists: a review of head-to-head clinical studies

(2014) Jennifer M. Trujillo et al.   Therapeutic Advances in Endocrinology and Metabolism

Inhibition of the methionine aminopeptidase 2 enzyme for the treatment of obesity

(2014) Amit Joharapurkar et al.   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Long-term effects of recombinant human growth hormone therapy in children with Prader–Willi syndrome

(2013) Peter M. Wolfgram et al.   CURRENT OPINION IN PEDIATRICS

GLP-1 analogues as a new treatment option for hypothalamic obesity in adults: report of nine cases

(2013) Flavius Zoicas et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Does des-acyl ghrelin improve glycemic control in obese diabetic subjects by decreasing acylated ghrelin levels?

(2013) Behiye Özcan et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET

(2013) Lieuwe Appel et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Inhibition of ghrelin O-acyltransferase attenuates food deprivation-induced increases in ingestive behavior

(2013) Brett J.W. Teubner et al.   HORMONES AND BEHAVIOR

Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS

(2013) L van Bloemendaal et al.   JOURNAL OF ENDOCRINOLOGY

Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats

(2013) Bo Hjorth Bentzen et al.   Obesity

Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women

(2013) T. E. Hughes et al.   Obesity

Peripheral Cannabinoid-1 Receptor Inverse Agonism Reduces Obesity by Reversing Leptin Resistance

(2012) Joseph Tam et al.   Cell Metabolism

A glucagon-like peptide-1 (GLP-1) receptor agonist in the treatment for hypothalamic obesity complicated by type 2 diabetes mellitus

(2012) S. K. Thondam et al.   CLINICAL ENDOCRINOLOGY

Prader-Willi Syndrome: Obesity due to Genomic Imprinting

(2012) Merlin G. Butler   CURRENT GENOMICS

Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques

(2012) P. Kievit et al.   DIABETES

An overview of the pharmacokinetics, efficacy and safety of liraglutide

(2012) Bruce Bode   DIABETES RESEARCH AND CLINICAL PRACTICE

The glucagon-like peptide-1 analog liraglutide suppresses ghrelin and controls diabetes in a patient with Prader-Willi syndrome

(2012) Miho Senda et al.   ENDOCRINE JOURNAL

MECHANISMS IN ENDOCRINOLOGY: Ghrelin: the differences between acyl- and des-acyl ghrelin

(2012) Patric J D Delhanty et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Editorial comment: Oxytocin, vasopressin and social behavior

(2012) Larry J. Young et al.   HORMONES AND BEHAVIOR

A reduced-energy intake, well-balanced diet improves weight control in children with Prader-Willi syndrome

(2012) J. L. Miller et al.   JOURNAL OF HUMAN NUTRITION AND DIETETICS

Ghrelin Level and Weight Loss After Laparoscopic Sleeve Gastrectomy and Gastric Mini-Bypass for Prader–Willi Syndrome in Chinese

(2012) Anthony K. W. Fong et al.   OBESITY SURGERY

Nutritional phases in Prader-Willi syndrome

(2011) Jennifer L. Miller et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART A

Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability

(2011) A. J. Garber   DIABETES CARE

Treating diabetes mellitus in Prader–Willi syndrome with Exenatide

(2011) Ian W. Seetho et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats

(2011) Elsmarieke van de Giessen et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Effects of a Single Dose of Exenatide on Appetite, Gut Hormones, and Glucose Homeostasis in Adults with Prader-Willi Syndrome

(2011) Lisa Sze et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

In adults with Prader–Willi syndrome, elevated ghrelin levels are more consistent with hyperphagia than high PYY and GLP-1 levels

(2011) Louise Purtell et al.   NEUROPEPTIDES

Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients

(2011) Maïthe Tauber et al.   Orphanet Journal of Rare Diseases

Cannabidiol inhibits the hyperphagia induced by cannabinoid-1 or serotonin-1A receptor agonists

(2011) América A. Scopinho et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity

(2010) Joseph Tam et al.   JOURNAL OF CLINICAL INVESTIGATION

Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat

(2010) Anne Marie D Axel et al.   NEUROPSYCHOPHARMACOLOGY

Motor problems in Prader–Willi syndrome: A systematic review on body composition and neuromuscular functioning

(2010) Linda Reus et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Unacylated Ghrelin Rapidly Modulates Lipogenic and Insulin Signaling Pathway Gene Expression in Metabolically Active Tissues of GHSR Deleted Mice

(2010) Patric J. D. Delhanty et al.   PLoS One

Ghrelin O-acyltransferase (GOAT) is essential for growth hormone-mediated survival of calorie-restricted mice

(2010) T.-J. Zhao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tesofensine – a novel potent weight loss medicine

(2009) Sheila A Doggrell   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Efficacy and Safety of Long-Term Continuous Growth Hormone Treatment in Children with Prader-Willi Syndrome

(2009) Roderick F. A. de Lind van Wijngaarden et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Critical Analysis of Bariatric Procedures in Prader-Willi Syndrome

(2009) AO Scheimann et al.   JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION

Ghrelin Induces Abdominal Obesity Via GHS-R-Dependent Lipid Retention

(2009) Jeffrey S. Davies et al.   MOLECULAR ENDOCRINOLOGY

Ghrelin concentrations in Prader-Willi syndrome (PWS) infants and children: changes during development

(2008) Andrea M. Haqq et al.   CLINICAL ENDOCRINOLOGY

Recommendations for the Diagnosis and Management of Prader-Willi Syndrome

(2008) A. P. Goldstone et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial

(2008) Arne Astrup et al.   LANCET

Oxytocin Deficiency Mediates Hyperphagic Obesity ofSim1Haploinsufficient Mice

(2008) Bassil M. Kublaoui et al.   MOLECULAR ENDOCRINOLOGY

Desacyl ghrelin inhibits the orexigenic effect of peripherally injected ghrelin in rats

(2008) Tobias Inhoff et al.   PEPTIDES

Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides

(2008) J. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ghrelin octanoylation mediated by an orphan lipid transferase

(2008) J. A. Gutierrez et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

(2007) A Thomas et al.   BRITISH JOURNAL OF PHARMACOLOGY